Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia, Pneumonia, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2002 |
| End Date: | March 2006 |
Multi-center Clinical Trial of the Bard Silver-coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)
The purpose of this study is to determine if the use of a silver-coated endotracheal tube
(ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non
silver-coated ETT in patients who have been mechanically ventilated for >= 24 hours.
(ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non
silver-coated ETT in patients who have been mechanically ventilated for >= 24 hours.
Nosocomial pneumonia is the leading cause of death from hospital-acquired
infections.Ventilator associated pneumonia (VAP) develops in a significant percentage of
patients who have been ventilated for at least 48 hours, and is associated with high
morbidity, mortality,and financial costs. Silver is a well-characterized antimicrobial
agent, and is the active agent in multiple medical products used to reduce or control
infection. Bard has developed a proprietary antimicrobial ETT, manufactured with a
hydrophilic coating containing a fine dispersion of silver salts.
This study compare the incidence and time to onset of VAP in patients intubated for >=24
hours with a proprietary silver-coated ETT versus those intubated for >= 24 hours with a
standard non-coated ETT.
infections.Ventilator associated pneumonia (VAP) develops in a significant percentage of
patients who have been ventilated for at least 48 hours, and is associated with high
morbidity, mortality,and financial costs. Silver is a well-characterized antimicrobial
agent, and is the active agent in multiple medical products used to reduce or control
infection. Bard has developed a proprietary antimicrobial ETT, manufactured with a
hydrophilic coating containing a fine dispersion of silver salts.
This study compare the incidence and time to onset of VAP in patients intubated for >=24
hours with a proprietary silver-coated ETT versus those intubated for >= 24 hours with a
standard non-coated ETT.
Inclusion Criteria:
- age > 18 years
- expected to be intubated for at least 24 hours
- able to sign Informed Consent
Exclusion Criteria:
- symptoms of bronchiectasis
- severe hemoptysis
- history of cystic fibrosis
- intubated > 12 hours within previous 30 days
- pregnancy
- participating in a competing trial
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials